{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Risk Categories:\n\nLow Risk:Patient has SMM, but none of the listed risk factors Low-Intermediate Risk: 1 risk factor is present High-Intermediate Risk: 2 risk factors are present High Risk: 3 risk factors are present\n\nRisk Factors:\n\n1. BM plasma cell % ≥50\n2. M-protein ≥ 3g/dL\n3. Involved/ un-involved free light chains ≥ 8","groups":[{"description":"Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks","id":"OG000","title":"Denosumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases.","type":"PRIMARY","unitOfMeasure":"proportion of participants"}